参麦注射液联合酒石酸美托洛尔在扩张型心肌病患者中的临床价值

Clinical Value of Shenmai Injection Combined with Metoprolol Tartrate in Patients with Dilated Cardiomyopathy

目的:观察参麦注射液联合酒石酸美托洛尔注射液对扩张型心肌病患者心功能及神经内分泌因子水平的影响。方法:选取汝州市第一人民医院2017年1月至2018年1月收治的80例扩张型心肌病患者进行研究,根据抽签法分为观察组40例和对照组40例。对照组使用酒石酸美托洛尔注射液治疗,观察组使用参麦注射液联合酒石酸美托洛尔注射液治疗,比较两组患者临床效果。结果:治疗前,两组患者左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)水平比较,差异均无统计学意义(P>0.05);治疗后,观察组患者的LVEF高于对照组,LVESD、LVEDD低于对照组,差异具有统计学意义(P<0.05)。治疗前,两组患者神经内分泌因子水平比较,差异均无统计学意义(P>0.05);治疗后,观察组患者神经内分泌因子水平均低于对照组,差异具有统计学意义(P<0.05)。结论:对扩张性心肌病患者应用参麦注射液联合酒石酸美托洛尔注射液治疗,可明显改善其心功能及神经内分泌因子水平。

Objective To observe the effects of Shenmai injection combined with metoprolol tartrate injection on cardiac function and neuroendocrine factors in patients with dilated cardiomyopathy.Methods 80 patients with dilated cardiomyopathy treated in Ruzhou first people's Hospital from January 2017 to January 2018 were selected for study.According to the method of drawing lots,they were divided into 40 cases in the observation group and 40 cases in the control group.The control group was treated with metoprolol tartrate injection,and the observation group was treated with Shenmai injection combined with metoprolol tartrate injection.The clinical effects of the two groups were compared.Results Before treatment,there was no significant difference in left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD)and left ventricular end diastolic diameter(LVEDd)between the two groups(P>0.05);after treatment,LVEF in the observation group was higher than that in the control group,and LVESD and LVEDd in the observation group were lower than those in the control group(P<0.05).Before treatment,there was no significant difference in the levels of neuroendocrine factors between the two groups(P>0.05);after treatment,the levels of neuroendocrine factors in the observation group were lower than those in the control group(P<0.05).Conclusion Shenmai injection combined with metoprolol tartrate injection can significantly improve the cardiac function and the level of neuroendocrine factors in patients with dilated cardiomyopathy.